Navigation Links
China Shenghuo Receives Notice from NYSE Amex LLC Regarding Listing Standards
Date:9/27/2010

most recent fiscal years. The Company was given an opportunity to submit a plan of compliance (a "Plan") to the AMEX by October 22, 2010 to demonstrate the Company's ability to regain compliance with Section 1003(a)(i) by March 22, 2012.

Pursuant to the Deficiency Letter, if the AMEX determines that the Company has made a reasonable demonstration in the Plan of an ability to regain compliance with the continued listing standards by March 22, 2012, the AMEX will accept the Plan. If the AMEX does not accept the Plan, or the Company does not make adequate progress and complete the actions outlined in the Plan by March 22, 2012, the AMEX will initiate delisting proceedings against the Company.

The Company's unaudited net loss attributable to stockholders for the six months ended June 30, 2010, was narrowed to $28,837 as compared to an unaudited net loss attributable to stockholders of $6.7 million for the six months ended June 30, 2009. The Company expects to be profitable for the nine months ending September 30, 2010 and for the full fiscal year ending December 31, 2010. The Plan that the Company will present to the AMEX will show that the Company projects that within the 18-month plan period its stockholders' equity will increase to the $2 million level as a result of its internally generated return to profitability. Should the Company issue equity, whether in a private or public offering during that period, it would accelerate meeting this target. However, there can be no assurance that the AMEX will find the Plan to be submitted to be acceptable or, even if accepted, that the Company will in fact generate sufficient net profit to achieve the requisite stockholders' equity threshold. Therefore, the Company can provide no assurances that it will regain compliance with the AMEX's continued listing standards, and its failure to do so could result in the delisting of the Company's common stock from the AMEX. Until the Company
'/>"/>

SOURCE China Shenghuo Pharmaceutical Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. China Medical Technologies Announces Plan of Senior Notes Offering
2. Special Event Providing Exclusive Access to Shanghais Booming Zhangjiang Pharma Valley Added to Agenda of First Annual SBS China Conference
3. China-Biotics Files New Patent Applications
4. China Cord Blood Corporation Announces Mandate for Share Repurchase Program
5. China Cord Blood Corporation Announces Framework Agreement Regarding Fourth License - Zhejiang Province
6. Reportlinker Adds Healthcare IT Market Outlook in China to 2016 - Hospital Information Systems and Medical Imaging Information Systems
7. China-Biotics, Inc. Comments on Market Rumors
8. Reportlinker Adds Clinical Trials in China
9. EntreMed Secures $5.1 Million in Registered Direct Offering and Enters into Agreement for Rights to License ENMD-2076 in China
10. China PharmaHub Corp. Begins Trading Under Stock Symbol CPHB Instead of WRLC
11. China Sky One Medical Updates Financial Guidance for 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Inc. (NYSE: RMD ) today announced results for ... 30, 2014.  Revenue for the quarter was $415.2 million, flat ... percent decrease on a constant currency basis). Net income was ... quarter ended June 30, 2013. Diluted earnings per share for ... to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. Wedbush Life ... Wednesday, August 13, 2014 at 9.10 a.m. Eastern Time ... York, NY Thursday, September 4, 2014 at 8.30 ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:7/31/2014)... 31, 2014  UBM Medica US announces that ... for oncologists, presents exclusive slide shows dealing with communication ... quality cancer care. Cancer Network, ... offers news, blogs, and podcasts about the latest clinical ... care: , End-of-life care is challenging for ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Cepheid to Webcast Upcoming Financial Presentations 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
... , NEW YORK, Dec. 7 ... updated efficacy and safety data as well as new ... in combination with bortezomib (Velcade(R)) (+/- dexamethasone) in patients ... "A Multicenter Phase 1/2 Study Evaluating the Safety and ...
... , ENGLEWOOD, Colo., Dec. 7 ... system, DoseEdge(TM), during this week,s ASHP Midyear Clinical Meeting ... patient safety and pharmacy efficiency through the management of ... easily into current pharmacy practice and techniques, while providing ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3
(Date:8/1/2014)... York, New York (PRWEB) August 01, 2014 ... http://www.gynecaremorcellatorlawsuit.com/ ) on behalf of women who allegedly experienced ... of power morcellators in gynecological surgeries, Bernstein Liebhard LLP ... to withdraw a number of power morcellators marketed by ... a report from The New York Times, some critics ...
(Date:8/1/2014)... benefits of a cancer diagnosis may improve health outcomes ... conducted by a researcher at the University of Houston ... writing intervention is the writing instruction. Otherwise, writing is ... a journal can be therapeutic, but oftentimes we don,t ... or not," said Qian Lu, assistant professor and director ...
(Date:8/1/2014)... August 01, 2014 On Monday, June ... NextGen User Symposium in San Francisco, CA. Now in ... the JW Marriott Union Square hotel. , “We are ... up to speed with ACA compliance issues,” Quirk Healthcare ... The symposium provides attendees guidance with NextGen implementation and ...
(Date:8/1/2014)... August 01, 2014 According to ... by Geography (Asia-Pacific, North America, Europe, & ROW), ... by Fuel Type (Gasoline & Diesel), by After-Treatment ... - Trends & Forecasts to 2019", defines and ... an analysis of major countries in all the ...
(Date:8/1/2014)... Scientists at Albert Einstein College of Medicine ... aid in digestion help keep the intestinal lining intact. ... , could yield new therapies for inflammatory bowel disease ... The research involved the intestinal microbiome, which contains some ... promoting or preventing disease is a major emerging field ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:'Normal' bacteria vital for keeping intestinal lining intact 2
... scientists implicates a new protein in obesity development and highlights ... resistance. Jorge Moscat, PhD, chair of UC,s ... ERK are involved in adipogeneis, (the development of adipocytes, or ... works together. The study is published online in ...
... , BOULDER, Colo. , ... of Functional Fitness on Walk the Talk ... Sam Iannetta , a champion powerlifter, tells—and shows—how ... healing injuries, whatever your fitness practice: yoga, cycling, ...
... SHANGHAI , Feb. 12 General Nutrition ... announced today that it, together with its parent company, has entered ... Bright Food (Group) Co., LTD (Bright Food). The partnership, to be ... market. Bright Food , a leading state-owned conglomerate in ...
... received male donors, plasma had worse outcomes, study found ... blood-banking industry discourages transfusing the blood product known as ... reaction in the recipients. , But now researchers have ... have advantages. , Plasma is the fluid in ...
... Touching down toe-first is less economical in humans, research shows , ... to walk heel-first than to walk on the balls of your ... Compared with heel-first walking, it takes 83 percent more energy to ... on the balls of your feet, according to the University of ...
... ... has just released their emWave® Desktop product. emWave Desktop works on both PC and ... ... has just released their emWave® Desktop product. emWave Desktop works on both PC and ...
Cached Medicine News:Health News:Research highlights role of protein pair in obesity regulation 2Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 2Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 3Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 4Health News:Restrictions on Plasma From Female Donors May Need Revisiting 2Health News:Heel-First Walking Conserves Energy 2Health News:HeartMath Announces the Release of Their New emWave Desktop Software 2Health News:HeartMath Announces the Release of Their New emWave Desktop Software 3Health News:HeartMath Announces the Release of Their New emWave Desktop Software 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: